	US 11,891,622 B2
	RPE cell populations and methods of generating same
Osnat Bohana-Kashtan, Tel-Mond (IL); Lior Ann Rosenberg Belmaker, Shoham (IL); and Ofer Wiser, Jerusalem (IL)
Assigned to CELL CURE NEUROSCIENCES LTD., Jerusalem (IL)
Appl. No. 15/539,473
Filed by Cell Cure Neurosciences Ltd., Jerusalem (IL)
PCT Filed Dec. 30, 2015, PCT No. PCT/IL2015/051269 § 371(c)(1), (2) Date Jun. 23, 2017, PCT Pub. No. WO2016/108239, PCT Pub. Date Jul. 7, 2016.
Claims priority of provisional application 62/195,309, filed on Jul. 22, 2015.
Claims priority of provisional application 62/116,972, filed on Feb. 17, 2015.
Claims priority of provisional application 62/097,753, filed on Dec. 30, 2014.
Prior Publication US 2018/0016553 A1, Jan. 18, 2018
Int. Cl. C12N 5/079 (2010.01); A61K 35/30 (2015.01)

CPC C12N 5/0621 (2013.01) [A61K 35/30 (2013.01); C12N 2500/02 (2013.01); C12N 2500/38 (2013.01); C12N 2501/115 (2013.01); C12N 2501/15 (2013.01); C12N 2501/16 (2013.01); C12N 2506/02 (2013.01); C12N 2533/52 (2013.01)]

17 Claims

1. A human retinal pigment epithelium (RPE) cell population for treatment of a retinal degenerative disease, comprising:

an effective amount of in vitro differentiated human RPE cells to treat the retinal degenerative disease,

wherein the human RPE cells are in suspension,

wherein at least 95% of the human RPE cells co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), and

wherein the human RPE cells have a ratio of apical secretion of pigment epithelium derived growth factor (PEDF): basal secretion of PEDF greater than 1 in a monolayer.